Approximately 350 million people are chronic carriers of hepatitis B virus (HBV) worldwide.
Introduction
Approximately 350 million people are chronic carriers of hepatitis B virus (HBV) worldwide. 1 In some countries, hepatocellular carcinoma and cirrhosis account for more than 50% of all deaths among HBV carriers. 2 Treatment of patients with hepatitis B has improved remarkably with the advent of oral nucleoside analogs such as lamivudine. 3, 4 Lamivudine administration has been shown to cause a rapid decrease in the serum HBV DNA level followed by a decrease in the alanine aminotransferase level and improvement of the liver histology. [5] [6] [7] [8] Therefore, measurement of serum HBV DNA is widely used in the clinical setting to monitor the effect of lamivudine.
It has been postulated that measurement of the HBV covalently closed circular (ccc) DNA level in hepatocytes is valuable in a different way than serum HBV DNA for monitoring the effects of antiviral therapy, because cccDNA is a key molecule in HBV replication. [9] [10] [11] [12] In practice, the intrahepatic HBV cccDNA level has been reported to be superior to serum HBV DNA for predicting a sustained virologic response to antiviral therapy, including lamivudine. 13 However, the measurement of cccDNA seems ill-suited for clinical use because it requires a liver biopsy. Thus, serum markers that reflect the cccDNA level in the liver are desired.
Recently, an HBV core-related antigen (HBVcrAg) assay developed by our laboratory has been shown to possibly correlate with the cccDNA level, especially during lamivudine therapy. [14] [15] [16] This possibility is based on the fact that transcription of messenger RNA from cccDNA and subsequent translation of viral proteins are not inhibited by nucleoside analogs such as lamivudine. The same has been said for synthesis of pregenomic RNA. 7 Therefore, in the present study, we measured serum HBV RNA and analyzed its virologic characteristics. In addition, changes in the serum HBV Background. Changes in the serum hepatitis B virus (HBV) RNA level during lamivudine therapy were compared to those in the serum HBV DNA and HBV core-related antigen (HBVcrAg) levels in 24 patients with chronic hepatitis B. Methods. For measurement of HBV RNA, total nucleic acid was extracted from serum samples and treated with RNase-free DNase I. After cDNA synthesis from extracted RNA, HBV RNA was measured by real-time detection polymerase chain reaction. Results. The peak fraction of HBV RNA in serum samples was consistent with peak fractions of HBV DNA and HBV core protein in a sucrose gradient analysis, indicating that HBV RNA was incorporated into virus particles. All levels of HBV DNA, HBV RNA, and HBVcrAg decreased gradually during lamivudine therapy (P < 0.001 for all). The amount of decrease from the start of lamivudine therapy was significantly higher for HBV DNA than for HBV RNA or HBVcrAg during 6 months of lamivudine therapy (P < 0.001 for all). However, a similar difference was not seen between HBV RNA and HBVcrAg levels during that period. The HBV RNA level was significantly correlated (P < 0.001 for all) with levels of HBV DNA and HBVcrAg both at the beginning and 2 months after the start of lamivudine therapy. Conclusions. HBV RNA is detectable in serum in a form indicating incorporation into virus particles, and its serum level might serve as a new viral marker with a significance different from that of HBV DNA in lamivudine therapy.
RNA level during lamivudine therapy were compared with those of serum HBV DNA and HBVcrAg levels to clarify whether HBV RNA measurement in serum has any clinical significance.
Patients and methods

Patients
A total of 24 patients with chronic hepatitis B consented to participate in the present study. They were selected from a pool of 32 consecutive patients who underwent lamivudine therapy at Shinshu University Hospital between July 2002 and June 2003. The patients comprised 18 men and 6 women, and their median age was 55 years (range, 39-79 years). Chronic hepatitis B was defined as positive HBV surface antigen for more than 6 months with liver histological findings consistent with chronic hepatitis. All patients had had elevated levels of serum alanine aminotransferase and HBV DNA for at least 6 months. Immediately prior to lamivudine administration, 16 patients were positive for HBV e antigen and 8 were positive for HBV e antibody but negative for HBV e antigen. The HBV genotype was C in all patients. Patients received 100-mg doses of lamivudine daily for at least 6 months. No patient was treated with other antiviral agents, such as interferon, before or during the present study, and all patients were negative for hepatitis C virus and human immunodeficiency virus antibodies. This study was approved by the ethics committee of our institution. Written informed consent was obtained from each patient.
Serum samples were collected at the start of lamivudine therapy, and at 2 and 6 months after commencement. Samples were stored frozen at −20°C or below until assayed.
Routine laboratory tests
HBV surface antigen, HBV e antigen, HBV e antibody, hepatitis C virus antibody, and human immunodeficiency virus antibody were measured by commercially available enzyme-linked immunosorbent assay kits (Abbott Japan, Tokyo, Japan). HBV genotypes were determined by the method reported by Mizokami et al. 17 and classified into six major genotypes, A to F.
The serum level of HBV DNA was determined using an Amplicor HBV Monitor kit (Roche Diagnostics, Tokyo, Japan), which has a quantitative range from 2.6 to 7.6 log copies/ml. Sera containing over 7.0 log copies/ml HBV DNA were diluted 10-or 100-fold with normal human serum and retested to obtain the end titer.
HBV core and core-related antigen assay
HBV core antigen (HBVcAg) and HBVcrAg in serum were measured using a chemiluminescence enzyme immunoassay as reported previously. 14, 15, 18 In brief, 100 µl serum was mixed with a pretreatment solution containing 15% sodium dodecyl sulfate. After incubation at 70°C for 30 min, 50 µl of pretreated serum was added to wells coated with monoclonal antibodies against denatured HBV core and e antigens (HB44, HB61, and HB114) and filled with 100 µl of assay buffer. The mixture was then incubated for 2 h at room temperature. After washing with buffer, either alkaline phosphataselabeled HB50 monoclonal antibody (specific for denatured HBV core antigen) or a mixture of HB91 and HB110 monoclonal antibodies (against denatured HBV core and e antigens) were added to wells and incubated for 1 h at room temperature. After another washing, CDP-Star with Emerald II (Applied Biosystems, Bedford, MA, USA) was added and plates were incubated for 20 min at room temperature. The relative chemiluminescence intensity was measured, and HBVcAg and HBVcrAg concentrations were read by comparison to a standard curve generated using recombinant pro-hepatitis B e antigen (amino acids −10 to 183 of the precore/core gene product). The concentrations of HBVcAg and HBVcrAg were expressed as units/ml, and the immunoreactivity of recombinant pro-hepatitis B e antigen at 10 fg/ml was defined as 1 unit/ml. The cutoff value of both assays was set at 3 log units/ml. 11 Sera containing over 7 log units/ml of antigen were diluted 10-or 100-fold in normal human serum and measured again to obtain the end titer.
HBV RNA assay
A High Pure Viral Nucleic Acid kit (Roche Diagnostics) was used for isolation of HBV RNA from serum. Briefly, 200 µl of serum was added to 250 µl of freshly prepared working solution (6 M guanidine-HCl; 10 mM urea; 10 mM Tris-HCl, pH 4.4; and 20% vol/vol Triton X-100) supplemented with 20 µg of poly(A) carrier RNA and 900 µg proteinase K. After incubation for 10 min at 72°C, 100 µl of isopropanol was added and the mixture was transferred into a High Pure filter tube combined with a collection tube. The filter tube was centrifuged for 1 min at 3500 g in a standard tabletop centrifuge at room temperature and combined with a new collection tube. The inhibitor removal buffer (5 M guanidine-HCl, 20 mM Tris-HCl, pH 6.6, in ethanol) was added to the upper reservoir and centrifuged for 1 min at 3500 g. After washing with 250 µl of wash buffer (20 mM NaCl, 2 mM Tris-HCl, pH 7.5, in ethanol), 80 µl of RNase-free DNase I solution (QIAGEN, Hilden, Germany) was added and incubated to digest HBV DNA for 15 min at room temperature. A volume of 200 µl of wash buffer was added to the filter tube, which was then centrifuged for 15 s at 5000 g. After being washed with 450 µl of buffer, the filter was placed in a new collection tube and 50 µl of RNase-and DNasefree water was added to elute the RNA. After centrifugation for 1 min at 3500 g, the eluted RNA was stored at −80°C.
Synthesis of cDNA was performed at 42°C for 30 min in a 20-µl reaction mixture containing 10 µl of the extracted RNA; 50 mM Tris-HCl, pH 8.3; 75 mM KCl; 3 mM MgCl 2 ; 1 mM dNTP (1 mM each dATP, dGTP, dCTP, and dTTP); 1 mM dithiothreitol; 100 nM reverse primer for the HBV surface gene (5′-GGTTGG TGAGTGATTGGAGGTT-3′; nt 345 to 324); 40 units of RNasin (TaKaRa, Kyoto, Japan); and 200 units of SuperScript II RNase H-reverse transcriptase (Invitrogen, Carlsbad, CA, USA). The reaction mixture was inactivated by heating to 70°C for 15 min and then cooled to −80°C until the real-time detection polymerase chain reaction (RTD-PCR) assay. A 4-µl aliquot of cDNA solution was used for RTD-PCR, which was performed with a Light Cycler system (Roche Diagnostics) as reported previously.
14 The two primers and TaqMan probe used were designed from a region of the HBV surface gene: forward primer, 5′-ACAACAT CAGGATTCCTAGGAC-3′ (nt 166 to 187); reverse primer as stated above (nt 345 to 324); and TaqMan probe, 5′-FAM-CAGAGTCTAGACTCGTGGTGGA CTTC-TAMRA-3′ (nt 244 to 269). An HBV genome (nt 20 to 1805) that had been subcloned into a pUC vector was used as an internal standard. The lower detection limit for the HBV RNA assay was set at 2.6 log copies/ml. HBV DNA was tested on extracted HBV RNA samples not having undergone the preceding process by RTD-PCR and was confirmed to be negative in all samples.
Sucrose density gradient ultracentrifugation
Serum (0.1 ml) was layered on a linear 10%-60% (wt/ wt) sucrose gradient, then centrifuged at 200 000 g (45 000 rpm) for 15 h at 4°C with a Beckman SW50.1 rotor (Beckman Coulter, Fullerton, CA, USA). In total, 24 fractions of 200 µl were collected by micropipette. Each fraction was diluted fivefold and tested for HBV DNA, HBV RNA, and HBVcAg.
Statistical analyses
Statistical analyses with the Mann-Whitney's U test, Friedman's test, and the Spearman rank correlation test were performed using the SPSS 10.0J statistical software package (SPSS, Chicago, IL, USA). A P value of less than 0.05 was considered statistically significant.
Results
Serum levels of HBV DNA (P < 0.001), HBV RNA (P < 0.001), and HBVcrAg (P < 0.001) all decreased significantly throughout the course of lamivudine therapy (Fig. 1) . The amount of decrease at 2 months following commencement of lamivudine therapy was significantly higher for HBV DNA than for HBV RNA or HBVcrAg (median, 2.45; 25%-75% range, 1.90-3.00 log copies/ml vs median, 0.40, 25%-75% range, 0.00-0.85 log copies/ml, P < 0.001, and median, 0.30, 25%-75% range, 0.10-0.65 log units/ml, P < 0.001, respectively). Similarly, the amount of decrease after 6 months of treatment was significantly higher for HBV DNA than for HBV RNA or HBVcrAg (median, 3.20; 25%-75% range, 2.00-4.55 log copies/ml vs median, 0.90; 25%-75% range, 0.45-1.90 log copies/ml, P < 0.001, and median, 0.90; 25%-75% range, 0.20-1.55 log units/ml, P < 0.001, respectively). The amount of decrease did not differ between HBV RNA and HBVcrAg at either 2 (P > 0.2) or 6 (P > 0.2) months after commencement.
As shown in Fig. 2 , the serum level of HBV RNA was significantly correlated with HBV DNA both at the start of lamivudine therapy (r = 0.801, P < 0.001) and 2 months afterward (r = 0.837, P < 0.001). Serum HBV RNA was also significantly correlated with that of HBVcrAg both at the start of treatment (r = 0.841, P < 0.001) and 2 months later (r = 0.777, P < 0.001). Ratios of HBV DNA and HBVcrAg levels to the HBV RNA level were calculated on log scale in patients who were positive for the above two parameters. The HBV DNA/ HBV RNA ratio at the start of lamivudine therapy (n = 21; median, 1.36, 25%-75% range, 1.20-1.71) decreased significantly (P < 0.001) at 2 months after treatment commencement (n = 15; median, 0.98; 25%-75% range, 0.86-1.11). On the other hand, the HBVcrAg per HBV RNA ratio at the start of treatment (n = 21; median, 1.32; 25%-75% range, 1.21-1.52) did not change (P > 0.2) after 2 months (n = 17; median, 1.36; 25%-75% range, 1.15-1.54). Serial serum samples obtained at the start of lamivudine therapy and at 1 and 2 months afterward were subjected to sucrose density gradient fractionation and tested for HBV DNA, HBV RNA, and HBVcAg. Each of the three viral markers showed a single peak for the same fraction (Fig. 3) , suggesting that HBV RNA was incorporated into the virus particles, similarly to HBV DNA. Viral particles containing HBV DNA were dominant at the start of treatment, while those containing HBV RNA became more prevalent 1 and 2 months afterward.
Discussion
Replication of the HBV DNA genome proceeds via pregenomic RNA transcribed from the cccDNA present in the nuclei of infected hepatocytes. 9, 11, 12 The pregenomic RNA is then packaged into nucleocapsids and reverse transcribed to form minus-strand DNA. Plus-strand DNA synthesis is initiated following degradation of the pregenome. It has been reported that nucleocapsids containing only minus-strand DNA can be enveloped and then secreted from hepatocytes. 19 Thus, HBV virions in circulation have been considered to contain only mature viral genomes. In spite of this, HBV RNA could be detected in serum in the present study. HBV RNA was considered to be incorporated into virus particles because HBV RNA made a single peak for the same fraction where both HBV DNA and HBVcAg made single peaks in sucrose gradient analyses conducted at three different time points during lamivudine therapy. Detection of HBV particles with RNA genome does not necessarily contradict the findings of the previous report, 19 since HBV RNA particles seemed to exist in only a small portion (0.1%-1%) of the HBV virions in patients without lamivudine administration. The possibility that our HBV RNA assay detected HBV DNA left undigested by the DNase was Detection of HBV RNA in serum has rarely been reported to date. Su et al. 20 reported the presence of full-length and truncated RNAs in serum, though their results seem to be quite different in nature because the HBV RNA that they observed was not incorporated into core particles. Zhang et al. 21 reported the existence of an RNA genome with partially reverse-transcribed minus-strand DNA in serum and speculated that the genome was in a virus particle. Such particles with HBV RNA accounted for about 1% of all HBV virions under untreated conditions, but became a major component under lamivudine administration. Although their analysis was done in a single patient, those observations are consistent with our observations that the rate of decrease of HBV DNA in serum was much faster than that of HBV RNA during lamivudine administration.
The HBVcrAg assay is a unique assay that measures the total amount of antigen coded by precore core genes such as HBV core and e antigens. 14, 15 During the HBVcrAg assay, core antigen was released from the pretreated HBV virion and denatured, along with free e antigen and e antigen/antibody-complex. The HBVcrAg assay employs monoclonal antibodies that are reactive with the common epitopes of denatured core and e antigens. Under these conditions, the HBVcrAg assay simultaneously measures the core and e antigens within a given sample, irrespective of their source of origin. Serum HBVcrAg levels reflect the viral load in the untreated state because these levels correlate linearly with those of HBV DNA. On the other hand, it has been reported that HBVcrAg levels show different characteristics than HBV DNA levels under lamivudine administration. 15, 16 It is noteworthy that HBVcrAg and HBV RNA levels both decreased significantly more slowly than HBV DNA after the beginning of lamivudine administration, but at a similar rate. This phenomenon is quite possible because synthesis of mRNA from cccDNA episomes and subsequent production of viral proteins is not inhibited by lamivudine like the synthesis of pregenomic RNA. Furthermore, it has been reported that the level of cccDNA decreases quite slowly during administration of nucleoside analogs, 22 indicating that serum levels of HBV RNA and HBVcrAg may be markers independent of the serum level of HBV DNA.
Measurement of serum HBV DNA is widely used for predicting and monitoring the effect of lamivudine therapy. However, a negative result of HBV DNA in serum does not necessarily indicate a good subsequent clinical course, because lamivudine-resistant strains often appear during drug administration and reactivation of HBV replication after discontinuation of treatment often occurs, even in patients who test negatively for serum HBV DNA during therapy. [23] [24] [25] Sung et al. 13 reported that the intrahepatic HBV cccDNA level at the end of lamivudine monotherapy or peginterferon and lamivudine combination therapy is a better predictor of a sustained virologic response than the serum HBV DNA level. Their conclusion seems quite reasonable because cccDNA in infected hepatocytes, not HBV in circulation, serves as a template for HBV pregenomic and messenger RNA in HBV replication. Although cccDNA in the liver is a good marker for monitoring the effect of antiviral therapy, it is not easy to measure clinically because it requires a liver biopsy. Thus, serum markers that reflect the cccDNA level in hepatocytes are more suitable for clinical use. We previously reported that the serum HBVcrAg level is an independent marker, different from the serum HBV DNA level, for predicting the appearance of lamivudine resistance, and suggested that the HBVcrAg level reflects the level of cccDNA in hepatocytes. 16 In the present study, serum levels of HBVcrAg and HBV RNA correlated significantly, and the two levels decreased in a similar manner during lamivudine therapy (Figs. 1 and 2) . These results further indicate that serum levels of both HBVcrAg and HBV RNA reflect the cccDNA level in hepatocytes since neither the synthesis of only messenger RNA, nor pregenomic RNA synthesized directly from cccDNA, which may be incorporated into viral particles, is inhibited by lamivudine.
In conclusion, HBV RNA that has been incorporated into viral particles is detectable in the serum of chronic HBV carriers. HBV RNA in serum is a new marker, which may reflect the cccDNA level in hepatocytes and may be useful for monitoring lamivudine therapy. We could not clarify the relationship between the HBV RNA level and clinical outcome in the present study. Thus, further studies are required to elucidate the clinical significance of HBV RNA in serum and its relationship to serum HBVcrAg.
